2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1197

Two Strategies for Recruiting Rural Faith-Based Organizations for a Fall-Prevention Exercise Intervention in a Population with High Rates of Arthritis
Abstract Number: 2872

Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis
Abstract Number: 1660

Two-Year Prospective Study of Patients with Rheumatic Disease on Dose Reduction of Biological Therapy
Abstract Number: 2874

Two-Years Survival of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis and Predictors Thereof in Real-Life Settings
Abstract Number: 3017

TYK2 and Systemic Sclerosis Susceptibility: a New Associated Locus in the IL-12 Pathway
Abstract Number: 1764

Type 1 Interferon in the Skin Stimulated By Ultraviolet B Light Generates Immune Suppression Mediated By Idoleamine 2,3-Dioxygenase 1
Abstract Number: 163

Ultrasonographic Assessment Covers Clinical Examination in the Localization of Ankle Pathology in Rheumatoid Arthritis
Abstract Number: 436

Ultrasonographic Disease Activity in Rheumatoid Arthritis Patients Who Are in Clinical Remission According to Different Remission Criteria: Should We Insist on Achieving Boolean Remission?
Abstract Number: 161

Ultrasonographic Evaluation of Rheumatoid Hand: Hand Disability and Disease Activity Correlation
Abstract Number: 177

Ultrasonographic Joint Evaluation in Daily Practice: What Is Its Contribution to Clinical Assessment?
Abstract Number: 169

Ultrasonographic Signs of Inflammation of Metatarsophalangeal Joints in Rheumatoid Arthritis Patients Who Are Treated to Target
Abstract Number: 162

Ultrasonography Versus Clinical Examination in Early DMARD-Naïve Rheumatoid Arthritis – a Comparative Study of Synovitis on the Individual Joint Level
Abstract Number: 441

Ultrasound Assessment of Early Response to Certolizumab Pegol Can Predict Future Response in Patients with Rheumatoid Arthritis
Abstract Number: 927

Ultrasound Assessment of Heel Entheses in Spondyloarthritis Patients: A Comparative Study with Radiography and Magnetic Resonance Imaging
Abstract Number: 168

Ultrasound Evaluation of the Efficacy of Biologic and Targeted Synthetic Dmards Toward Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort in Japan

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].